Incretin Hormone Secretion in Women with Polycystic Ovary Syndrome: Roles of Obesity, Insulin Sensitivity and Treatment with Metformin and GLP-1s

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Mar 28

PMID 38540265

Authors

Andrea Etrusco

Mislav Mikus

Antonio Damato

Fabio Barra

Petar Planinic

Trpimir Goluza

Giovanni Buzzaccarini

Jelena Marusic

Mara Tesanovic

Antonio Simone Lagana

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this narrative review is to describe the mechanisms that are responsible for the development of infertility and PCOS, with a focus on the role of obesity, insulin sensitivity and treatment with metformin and GLP-1s.

Methods: The relevant publications were identified after systematic queries of the following sources: PubMed, Google Scholar, Web of Science, and publishers' databases, complemented by a cross-check of the reference lists. We used a combination of the search terms "polycystic ovary syndrome", "obesity" and "insulin resistance" with "metformin", "exenatide", "liraglutide", "semaglutide", "orlistat" and terms relevant to the topic of each paragraph (e.g., "pathophysiology", "metabolism", "infertility", "treatment").

Results: All articles describing the mechanisms responsible for the development of infertility and PCOS, with a focus on the role of obesity, insulin sensitivity and treatment with metformin and GLP-1s, were considered for this review.

Conclusions: The existing research on GLP-1 receptor agonists (GLP-1RAs) has not conclusively established a specific therapeutic use for these drugs. Additionally, the efficacy of the newer generation of GLP-1RAs, particularly in terms of dosage and duration of exposure, warrants more extensive research. Understanding the optimal dosing and treatment duration could significantly enhance the therapeutic use of GLP-1RAs in managing PCOS and its associated conditions.

Citing Articles

Association between estimated glucose disposal rate and female infertility: a cross-sectional study.

Li M, Zhang L, Li X, Yan W Front Endocrinol (Lausanne). 2024; 15:1474738.

PMID: 39600947 PMC: 11588443. DOI: 10.3389/fendo.2024.1474738.

Validation of the follicular and ovarian thresholds by an 18-MHz ultrasound imaging in polycystic ovary syndrome: a pilot cutoff for North African patients.

Ach T, Guesmi A, Kalboussi M, Ben Abdessalem F, Mraihi E, El Mhabrech H Ther Adv Reprod Health. 2024; 18:26334941241270372.

PMID: 39170801 PMC: 11337176. DOI: 10.1177/26334941241270372.

Polycystic ovarian syndrome elevates the distress of sexual pain in Iranian women with infertility.

Tahmasbi B, Eshraghi R, Amini-Tehrani M, Zamanian H, Ilami A BMC Womens Health. 2024; 24(1):364.

PMID: 38909223 PMC: 11193243. DOI: 10.1186/s12905-024-03181-1.

Decisional needs and interventions for young women considering contraceptive options: an umbrella review.

Bortoli M, Kantymir S, Pacheco-Brousseau L, Dahl B, Hansen E, Lewis K BMC Womens Health. 2024; 24(1):336.

PMID: 38851748 PMC: 11162067. DOI: 10.1186/s12905-024-03172-2.

Association between physical activity and risk of premenstrual syndrome among female college students: a systematic review and meta-analysis.

Yang H, Ma Y, Wang Y, Fu C, Liu W, Li W BMC Womens Health. 2024; 24(1):307.

PMID: 38783362 PMC: 11112772. DOI: 10.1186/s12905-024-03147-3.

References

Salamun V, Jensterle M, Janez A, Vrtacnik Bokal E . Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018; 179(1):1-11. DOI: 10.1530/EJE-18-0175. View

Apridonidze T, Essah P, Iuorno M, Nestler J . Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004; 90(4):1929-35. DOI: 10.1210/jc.2004-1045. View

Pugliese G, de Alteriis G, Muscogiuri G, Barrea L, Verde L, Zumbolo F . Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?. J Endocrinol Invest. 2023; 46(9):1761-1774. PMC: 10372121. DOI: 10.1007/s40618-023-02084-6. View

Lyu X, Lyu T, Wang X, Zhu H, Pan H, Wang L . The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2021; 2021:6616693. PMC: 7910049. DOI: 10.1155/2021/6616693. View

Snider A, Wood J . Obesity induces ovarian inflammation and reduces oocyte quality. Reproduction. 2019; 158(3):R79-R90. DOI: 10.1530/REP-18-0583. View

Sekar N, Garmey J, Veldhuis J . Mechanisms underlying the steroidogenic synergy of insulin and luteinizing hormone in porcine granulosa cells: joint amplification of pivotal sterol-regulatory genes encoding the low-density lipoprotein (LDL) receptor, steroidogenic acute regulatory.... Mol Cell Endocrinol. 2000; 159(1-2):25-35. DOI: 10.1016/s0303-7207(99)00203-8. View

Liu J, Zhao Y, Chen L, Li R, Ning Y, Zhu X . Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. Mol Med Rep. 2022; 26(1). PMC: 9175273. DOI: 10.3892/mmr.2022.12734. View

Carmina E, Lobo R . Comparing Lean and Obese PCOS in Different PCOS Phenotypes: Evidence That the Body Weight Is More Important than the Rotterdam Phenotype in Influencing the Metabolic Status. Diagnostics (Basel). 2022; 12(10). PMC: 9600591. DOI: 10.3390/diagnostics12102313. View

Hernandez-Jimenez J, Barrera D, Espinoza-Simon E, Gonzalez J, Ortiz-Hernandez R, Escobar L . Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. Gynecol Endocrinol. 2021; 38(1):2-9. DOI: 10.1080/09513590.2021.2003326. View

10.

Lagana A, Barbaro L, Pizzo A . Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2014; 291(5):1181-6. DOI: 10.1007/s00404-014-3552-6. View

11.

Teede H, Deeks A, Moran L . Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8:41. PMC: 2909929. DOI: 10.1186/1741-7015-8-41. View

12.

Cioana M, Deng J, Nadarajah A, Hou M, Qiu Y, Chen S . Prevalence of Polycystic Ovary Syndrome in Patients With Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(2):e2147454. PMC: 8848210. DOI: 10.1001/jamanetworkopen.2021.47454. View

13.

Tak Y, Lee S . Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. World J Mens Health. 2020; 39(2):208-221. PMC: 7994651. DOI: 10.5534/wjmh.200010. View

14.

The Lancet Diabetes Endocrinology . The obesity-cancer link: of increasing concern. Lancet Diabetes Endocrinol. 2020; 8(3):175. DOI: 10.1016/S2213-8587(20)30031-0. View

15.

Sanchez-Garrido M, Tena-Sempere M . Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol Metab. 2020; 35:100937. PMC: 7115104. DOI: 10.1016/j.molmet.2020.01.001. View

16.

Salvatore T, Pafundi P, Morgillo F, Di Liello R, Galiero R, Nevola R . Metformin: An old drug against old age and associated morbidities. Diabetes Res Clin Pract. 2020; 160:108025. DOI: 10.1016/j.diabres.2020.108025. View

17.

Frossing S, Nylander M, Kistorp C, Skouby S, Faber J . Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Endocr Connect. 2018; 7(1):115-123. PMC: 5754509. DOI: 10.1530/EC-17-0327. View

18.

Vitale S, Fulghesu A, Mikus M, Watrowski R, DAlterio M, Lin L . The Translational Role of miRNA in Polycystic Ovary Syndrome: From Bench to Bedside-A Systematic Literature Review. Biomedicines. 2022; 10(8). PMC: 9405312. DOI: 10.3390/biomedicines10081816. View

19.

Ortega I, Villanueva J, Wong D, Cress A, Sokalska A, Stanley S . Resveratrol potentiates effects of simvastatin on inhibition of rat ovarian theca-interstitial cells steroidogenesis. J Ovarian Res. 2014; 7:21. PMC: 3940290. DOI: 10.1186/1757-2215-7-21. View

20.

Li X, Cui P, Jiang H, Guo Y, Pishdari B, Hu M . Reversing the reduced level of endometrial GLUT4 expression in polycystic ovary syndrome: a mechanistic study of metformin action. Am J Transl Res. 2015; 7(3):574-86. PMC: 4448196. View